• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌中的谷氨酰胺代谢重编程

Glutamine metabolic reprogramming in hepatocellular carcinoma.

作者信息

Ye Yanyan, Yu Bodong, Wang Hua, Yi Fengming

机构信息

Department of Ultrasound, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

The Second Clinical Medical College of Nanchang University, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

出版信息

Front Mol Biosci. 2023 Aug 11;10:1242059. doi: 10.3389/fmolb.2023.1242059. eCollection 2023.

DOI:10.3389/fmolb.2023.1242059
PMID:37635935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10452011/
Abstract

Hepatocellular carcinoma (HCC) is a lethal disease with limited management strategies and poor prognosis. Metabolism alternations have been frequently unveiled in HCC, including glutamine metabolic reprogramming. The components of glutamine metabolism, such as glutamine synthetase, glutamate dehydrogenase, glutaminase, metabolites, and metabolite transporters, are validated to be potential biomarkers of HCC. Increased glutamine consumption is confirmed in HCC, which fuels proliferation by elevated glutamate dehydrogenase or upstream signals. Glutamine metabolism also serves as a nitrogen source for amino acid or nucleotide anabolism. In addition, more glutamine converts to glutathione as an antioxidant in HCC to protect HCC cells from oxidative stress. Moreover, glutamine metabolic reprogramming activates the mTORC signaling pathway to support tumor cell proliferation. Glutamine metabolism targeting therapy includes glutamine deprivation, related enzyme inhibitors, and transporters inhibitors. Together, glutamine metabolic reprogramming plays a pivotal role in HCC identification, proliferation, and progression.

摘要

肝细胞癌(HCC)是一种致命疾病,治疗策略有限且预后不佳。HCC中经常出现代谢改变,包括谷氨酰胺代谢重编程。谷氨酰胺代谢的组成部分,如谷氨酰胺合成酶、谷氨酸脱氢酶、谷氨酰胺酶、代谢物和代谢物转运体,已被证实是HCC的潜在生物标志物。HCC中谷氨酰胺消耗增加,这通过升高的谷氨酸脱氢酶或上游信号促进增殖。谷氨酰胺代谢还作为氨基酸或核苷酸合成代谢的氮源。此外,在HCC中,更多的谷氨酰胺转化为谷胱甘肽作为抗氧化剂,以保护HCC细胞免受氧化应激。此外,谷氨酰胺代谢重编程激活mTORC信号通路以支持肿瘤细胞增殖。针对谷氨酰胺代谢的治疗包括谷氨酰胺剥夺、相关酶抑制剂和转运体抑制剂。总之,谷氨酰胺代谢重编程在HCC的识别、增殖和进展中起关键作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/450c/10452011/3fa0047addf8/fmolb-10-1242059-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/450c/10452011/a8285e0bc7aa/fmolb-10-1242059-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/450c/10452011/f6d875e7bf4c/fmolb-10-1242059-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/450c/10452011/3fa0047addf8/fmolb-10-1242059-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/450c/10452011/a8285e0bc7aa/fmolb-10-1242059-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/450c/10452011/f6d875e7bf4c/fmolb-10-1242059-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/450c/10452011/3fa0047addf8/fmolb-10-1242059-g003.jpg

相似文献

1
Glutamine metabolic reprogramming in hepatocellular carcinoma.肝细胞癌中的谷氨酰胺代谢重编程
Front Mol Biosci. 2023 Aug 11;10:1242059. doi: 10.3389/fmolb.2023.1242059. eCollection 2023.
2
AGC1-mediated Metabolic Reprogramming and Autophagy Sustain Survival of Hepatocellular Carcinoma Cells under Glutamine Deprivation.AGC1介导的代谢重编程和自噬维持谷氨酰胺缺乏条件下肝癌细胞的存活。
Cell Biochem Biophys. 2024 Sep;82(3):2037-2053. doi: 10.1007/s12013-024-01311-y. Epub 2024 May 24.
3
OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.OGDHL基因沉默通过重编程谷氨酰胺代谢促进肝细胞癌。
J Hepatol. 2020 May;72(5):909-923. doi: 10.1016/j.jhep.2019.12.015. Epub 2019 Dec 30.
4
Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.SLC25A15 基因缺失通过重编程谷氨酰胺代谢促进缺氧反应基因促进肝细胞癌。
J Hepatol. 2024 Feb;80(2):293-308. doi: 10.1016/j.jhep.2023.10.024. Epub 2023 Oct 30.
5
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.肝细胞癌的代谢失调与新兴治疗靶点
Acta Pharm Sin B. 2022 Feb;12(2):558-580. doi: 10.1016/j.apsb.2021.09.019. Epub 2021 Sep 25.
6
Metformin-Loaded Hyaluronic Acid-Derived Carbon Dots for Targeted Therapy against Hepatocellular Carcinoma by Glutamine Metabolic Reprogramming.载二甲双胍的透明质酸衍生碳点通过谷氨酰胺代谢重编程靶向治疗肝细胞癌。
Mol Pharm. 2023 Dec 4;20(12):6391-6406. doi: 10.1021/acs.molpharmaceut.3c00772. Epub 2023 Nov 7.
7
Glutamine metabolism, a double agent combating or fuelling hepatocellular carcinoma.谷氨酰胺代谢,对抗或助长肝细胞癌的双面角色。
JHEP Rep. 2024 Mar 27;6(5):101077. doi: 10.1016/j.jhepr.2024.101077. eCollection 2024 May.
8
SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.SMYD2 通过 c-Myc/GLS1 轴重编程谷氨酰胺代谢促进肝癌进展。
Cells. 2022 Dec 21;12(1):25. doi: 10.3390/cells12010025.
9
Glutamine metabolism in breast cancer and possible therapeutic targets.乳腺癌中的谷氨酰胺代谢及潜在治疗靶点。
Biochem Pharmacol. 2023 Apr;210:115464. doi: 10.1016/j.bcp.2023.115464. Epub 2023 Feb 26.
10
Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment.全基因组 CRISPR/Cas9 文库筛选揭示了谷氨酰胺限制饮食与丙酮酸代谢抑制联合应用是有效的肝癌治疗方法。
Adv Sci (Weinh). 2022 Dec;9(34):e2202104. doi: 10.1002/advs.202202104. Epub 2022 Oct 30.

引用本文的文献

1
Nuclear functional role of metabolic enzymes and related metabolites: Focus on gene expression regulation.代谢酶及相关代谢物的核功能作用:聚焦于基因表达调控。
Mol Metab. 2025 Aug 7;100:102233. doi: 10.1016/j.molmet.2025.102233.
2
Revisited: Isoforms, Expression, Functions, and Unresolved Questions.再探:异构体、表达、功能及未解决的问题。
Biomolecules. 2025 Jun 16;15(6):875. doi: 10.3390/biom15060875.
3
Glutamate promotes CCL2 expression to recruit tumor-associated macrophages by restraining EZH2-mediated histone methylation in hepatocellular carcinoma.

本文引用的文献

1
PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma.PNO1 通过 GSH 代谢重编程抑制肝癌细胞自噬性铁死亡。
Cell Death Dis. 2022 Nov 29;13(11):1010. doi: 10.1038/s41419-022-05448-7.
2
Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment.谷氨酰胺代谢的重编程及其对肿瘤微环境中免疫反应的影响。
Cell Commun Signal. 2022 Jul 27;20(1):114. doi: 10.1186/s12964-022-00909-0.
3
Tumor-associated Exosomes Are Involved in Hepatocellular Carcinoma Tumorigenesis, Diagnosis, and Treatment.
谷氨酸通过抑制EZH2介导的组蛋白甲基化促进CCL2表达,以募集肝癌中的肿瘤相关巨噬细胞。
Oncoimmunology. 2025 Dec;14(1):2497172. doi: 10.1080/2162402X.2025.2497172. Epub 2025 Apr 24.
4
Cuproplasia and cuproptosis in hepatocellular carcinoma: mechanisms, relationship and potential role in tumor microenvironment and treatment.肝细胞癌中的铜代谢异常与铜死亡:机制、关系及其在肿瘤微环境和治疗中的潜在作用
Cancer Cell Int. 2025 Apr 9;25(1):137. doi: 10.1186/s12935-025-03683-4.
5
Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer.慢性肝病和肝癌患者健康的生物社会决定因素
Cancers (Basel). 2025 Feb 28;17(5):844. doi: 10.3390/cancers17050844.
6
Interactions between the metabolic reprogramming of liver cancer and tumor microenvironment.肝癌代谢重编程与肿瘤微环境之间的相互作用。
Front Immunol. 2025 Feb 14;16:1494788. doi: 10.3389/fimmu.2025.1494788. eCollection 2025.
7
Multi-omics integration analysis of the amino-acid metabolism-related genes identifies putatively causal variants of ACCS associated with hepatitis B virus-related hepatocellular carcinoma survival.氨基酸代谢相关基因的多组学整合分析确定了与乙型肝炎病毒相关肝细胞癌生存相关的假定因果变异。
BMC Cancer. 2025 Feb 18;25(1):284. doi: 10.1186/s12885-025-13604-3.
8
Drug Repurposing: A Conduit to Unravelling Metabolic Reprogramming for Cancer Treatment.药物再利用:揭示癌症治疗中代谢重编程的途径。
Mini Rev Med Chem. 2025;25(8):601-627. doi: 10.2174/0113895575339660250106093738.
9
A glutamine metabolish-associated prognostic model to predict prognosis and therapeutic responses of hepatocellular carcinoma.谷氨酰胺代谢相关预后模型预测肝细胞癌的预后和治疗反应。
Biol Direct. 2024 Nov 20;19(1):118. doi: 10.1186/s13062-024-00567-x.
10
Hepatitis C virus infection and Parkinson's disease: insights from a joint sex-stratified BioOptimatics meta-analysis.丙型肝炎病毒感染与帕金森病:来自联合性别分层 BioOptimatics 荟萃分析的新见解。
Sci Rep. 2024 Oct 1;14(1):22838. doi: 10.1038/s41598-024-73535-0.
肿瘤相关外泌体参与肝细胞癌的肿瘤发生、诊断和治疗。
J Clin Transl Hepatol. 2022 Jun 28;10(3):496-508. doi: 10.14218/JCTH.2021.00425. Epub 2022 Jan 4.
4
Noncellular components in the liver cancer stem cell niche: Biology and potential clinical implications.肝癌干细胞龛中非细胞成分:生物学及潜在临床意义。
Hepatology. 2023 Sep 1;78(3):991-1005. doi: 10.1002/hep.32629. Epub 2022 Jul 5.
5
Deletion of Lactate Dehydrogenase-A Impairs Oncogene-Induced Mouse Hepatocellular Carcinoma Development.缺失乳酸脱氢酶 A 可抑制癌基因诱导的小鼠肝细胞癌的发展。
Cell Mol Gastroenterol Hepatol. 2022;14(3):609-624. doi: 10.1016/j.jcmgh.2022.06.003. Epub 2022 Jun 15.
6
Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt/β-Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma.非酒精性脂肪性肝病诱导的肝细胞癌中肝脏氧化应激相关因素与Wnt/β-连环蛋白信号通路激活之间的关联
Cancers (Basel). 2022 Apr 20;14(9):2066. doi: 10.3390/cancers14092066.
7
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.肝细胞癌的分子发病机制和系统治疗。
Nat Cancer. 2022 Apr;3(4):386-401. doi: 10.1038/s43018-022-00357-2. Epub 2022 Apr 28.
8
Ginsenoside Rk1 regulates glutamine metabolism in hepatocellular carcinoma through inhibition of the ERK/c-Myc pathway.人参皂苷 Rk1 通过抑制 ERK/c-Myc 通路调节肝癌细胞中的谷氨酰胺代谢。
Food Funct. 2022 Apr 4;13(7):3793-3811. doi: 10.1039/d1fo03728e.
9
Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.巨胞饮作用是半胱氨酸获取的替代途径,并减轻索拉非尼诱导的肝细胞癌中的铁死亡。
J Exp Clin Cancer Res. 2022 Mar 14;41(1):98. doi: 10.1186/s13046-022-02296-3.
10
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.肝细胞癌的代谢失调与新兴治疗靶点
Acta Pharm Sin B. 2022 Feb;12(2):558-580. doi: 10.1016/j.apsb.2021.09.019. Epub 2021 Sep 25.